Literature DB >> 22761106

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.

Michael P Bogenschutz1, Jessica M Pommy.   

Abstract

Alcohol and drug addiction are major public health problems, and existing treatments are only moderately effective. Although there has been interest for over half a century in the therapeutic use of classic hallucinogens to treat addictions, clinical research with these drugs was halted at an early stage in the early 1970s, leaving many fundamental questions unanswered. In the past two decades, clinical research on classic hallucinogens has resumed, although addiction treatment trials are only now beginning. The purpose of this paper is to provide a targeted review of the research most relevant to the therapeutic potential of hallucinogens, and to integrate this information with current thinking about addiction and recovery. On the basis of this information, we present a heuristic model which organizes a number of hypotheses that may be tested in future research. We conclude that existing evidence provides a convincing rationale for further research on the effects of classic hallucinogens in the treatment of addiction.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761106     DOI: 10.1002/dta.1376

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  22 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

2.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

3.  Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Authors:  Simon D Brandt; Pierce V Kavanagh; Geraldine Dowling; Brian Talbot; Folker Westphal; Markus R Meyer; Hans H Maurer; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-04-21       Impact factor: 3.345

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 5.  Lysergic acid diethylamide: a drug of 'use'?

Authors:  Saibal Das; Preeti Barnwal; Anand Ramasamy; Sumalya Sen; Somnath Mondal
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-23

6.  Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Authors:  Dimitri Daldegan-Bueno; Lucas Oliveira Maia; Carolina Marcolino Massarentti; Luís Fernando Tófoli
Journal:  Psychopharmacology (Berl)       Date:  2022-02-18       Impact factor: 4.530

7.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

8.  The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women.

Authors:  Elena Argento; Melissa Braschel; Zach Walsh; M Eugenia Socias; Kate Shannon
Journal:  J Psychopharmacol       Date:  2018-09-26       Impact factor: 4.153

Review 9.  Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.

Authors:  Jennifer M Loftis; Marilyn Huckans
Journal:  Pharmacol Ther       Date:  2013-04-28       Impact factor: 12.310

10.  Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.

Authors:  Brian Rush; Olivia Marcus; Sara García; Anja Loizaga-Velder; Gabriel Loewinger; Ariane Spitalier; Fernando Mendive
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.